1. Home
  2. SOPH vs XBIT Comparison

SOPH vs XBIT Comparison

Compare SOPH & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

HOLD

Current Price

$8.35

Market Cap

462.3M

Sector

Health Care

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

N/A

Current Price

$2.17

Market Cap

66.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOPH
XBIT
Founded
2011
2005
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
462.3M
66.8M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
SOPH
XBIT
Price
$8.35
$2.17
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $7.50
N/A
AVG Volume (30 Days)
★ 624.7K
43.6K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.09
N/A
Revenue Next Year
$19.57
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.75
$2.09
52 Week High
$8.98
$3.44

Technical Indicators

Market Signals
Indicator
SOPH
XBIT
Relative Strength Index (RSI) 57.08 40.04
Support Level $4.63 N/A
Resistance Level $8.84 $2.48
Average True Range (ATR) 0.40 0.04
MACD -0.04 0.00
Stochastic Oscillator 68.38 15.38

Price Performance

Historical Comparison
SOPH
XBIT

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: